A doctor and a psychologist say Health Canada’s move to allow physicians to request restricted psychedelic drugs for patients as part of their psychotherapy is a positive step toward transforming mental-health care.
But they say the recent change to the Special Access Program isn’t enough.
“We still have a huge amount of work to do because these medicines could really, really revolutionize the entire mental health-care field,” said Dr. Michael Verbora, who works as a medical director at the Field Trip Health therapy centre in Toronto.
“I don’t want to get too far ahead of where the science is … but I do really, really believe that if people have a process to start their own healing, it can lead to a much better world for most people.”
Psychedelic assisted therapy involves ingesting consciousness-altering substances — including psilocybin, ketamine, LSD or MDMA (the active ingredient in ecstasy) — in a clinical setting as part of more traditional psychotherapy.
Health Canada has said requests will be considered on a case-by-case basis for a “serious or life-threatening condition” and where other conventional treatments have failed, are unsuitable for the patient or are not available in Canada.
Verbora said the change isn’t designed to have a wait list, because it’s meant for emergencies. Health Canada has said applications will be processed within two days, but it’s unclear when a decision would be made.
What it has done is streamline potential access to restricted drugs, Verbora said.
“Unfortunately, if you have a terminal illness, you don’t have much life left in you. You don’t have time to apply to the government and wait months to get an exemption.”
Edmonton-based psychologist Brian Welling calls the approach “revolutionary.”
“This is the greatest leap forward in mental-health care since the invention of psychotherapy,” he said.
“I’ve used psychedelics many, many times. I didn’t have a serious or life-threatening condition, but for my own personal problems and part of my own spiritual journey, these experiences have been life-changing.
Verbora, who filed his first application on behalf of a patient this week, said one of the biggest challenges is that more physicians need education on psychedelic therapy.
“The responsibility really falls on the physician to do all the paperwork, which is like to write 100 prescriptions in the time that I do one of these applications,’ he said. “Then I’ll have to access the drug. I’ll have to store the drug. I’ll have to educate the patient on the drug.”
Ronan Levy, co-founder ofField Trip Health,said most applications except the most severe will probably be rejected.
He said he hopes Health Canada’s criteria for approval of psychedelics expand in the future.
The government has said the regulatory amendment does not signal “an intent towards the decriminalization or legalization of restricted drugs.”
However, that conversation needs to start, said Verbora.
“We have a long way to go to help the millions of people around the world that unfortunately suffer from mental-health issues and (their) growing burden.”
All three men suggest that can happen by removing the stigma around psychedelics.
“When done in the right circumstances, with the proper oversight, with trained clinicians who can support the experience, the outcomes can be fantastic,” Levy said.
“That leads to people who have greater emotional resilience, people who are more able to adapt to circumstances like a global pandemic.”
This story was produced with the financial assistance of the Facebook and Canadian Press News Fellowship
Fakiha Baig, The Canadian Press
Like us on Facebook and follow us on Twitter.